Previous 10 | Next 10 |
Entities controlled by Randal J. Kirk sold 1,567,633 shares of Halo Therapeutics (NASDAQ: HALO ) in open market transactions between June 10 and July 2, 2019 for aggregate net proceeds of $26.1M, according to an SEC filing. More news on: Halozyme Therapeutics, Inc., Healt...
Halozyme ( HALO +1.4% ) enters into an agreement with the NIH's National Institute of Allergy and Infectious Diseases' Vaccine Research Center aimed at leveraging HALO's ENHANZE drug delivery technology to develop subcutaneous formulations of broadly neutralizing antibodies against HIV. ...
SAN DIEGO , June 25, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases' Vaccine Research Center (VRC), part of the National Insti...
At its R&D Day today, argenx ( ARGX +0.5% ) will present data on two new pipeline candidates: ARGX-117, a next-generation complement-targeting antibody against C2 and ARGX-118, an antibody targeting a protein called Galectin-10 that plays a key role in severe asthma, in-licensed from B...
Halozyme (NASDAQ: HALO ) announces that argenx has selected a second target under ENHANZE Technology collaboration and license agreement announced in February 2019. More news on: Halozyme Therapeutics, Inc., Healthcare stocks news, Read more ...
SAN DIEGO , May 22, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that argenx has selected a second target under the collaboration and license agreement the companies announce...
SAN DIEGO , May 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the Bank of America Merrill Lynch Health Care Conference 2019 in Las Vegas, NV. Laurie Stelzer , ...
Halozyme Therapeutics, Inc. (HALO) Q1 2019 Earnings Conference Call May 07, 2019, 16:30 ET Company Participants Albert Kildani - VP, IR & Corporate Communications Laurie Stelzer - SVP & CFO Helen Torley - President, CEO & Director Dimitrios Chondros - Chief Medical ...
Halozyme Therapeutics (NASDAQ: HALO ): Q1 GAAP EPS of $0.01 misses by $0.03 . Revenue of $56.9M (+84.3% Y/Y) misses by $10.9M . Press Release More news on: Halozyme Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,
SAN DIEGO , May 7, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results for the first quarter ended March 31, 2019 and provided an update on recent corporate...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...